Polman C H
Free University Hospital, Amsterdam, The Netherlands.
Baillieres Clin Neurol. 1997 Oct;6(3):511-24.
This short review concentrates on immunomodulatory disease-modifying approaches that are under development for the treatment of multiple sclerosis based on present concepts of the immunopathogenesis of the disease that especially involve T-cells and macrophages as being prominently involved in inducing tissue destruction and on the advances that have been made in recent years by studying other treatment interventions that have been applied and that have been shown to be either successful (interferon beta, copolymer-1) or unsuccessful (many others).
本简短综述聚焦于正在研发的免疫调节性疾病修正疗法,这些疗法基于目前对多发性硬化症免疫发病机制的认识,该机制尤其涉及在诱导组织破坏中起显著作用的T细胞和巨噬细胞,同时也关注近年来在研究其他已应用的治疗干预措施方面取得的进展,这些干预措施已被证明有的成功(干扰素β、共聚物-1),有的失败(许多其他措施)。